Children's CBD Gummies: A Scientific Review of Evidence - Mustaf Medical
Understanding Cannabidiol (CBD) for Children
Recent health and wellness conversations have increasingly included cannabidiol, or CBD, a compound derived from the Cannabis sativa plant. With growing research into its properties, interest has expanded to its potential applications for various health concerns. This has led to questions about CBD products, including gummies, and their relevance for pediatric populations. While the U.S. Food and Drug Administration (FDA) has approved one purified CBD product, Epidiolex, for treating seizures associated with rare forms of epilepsy in children, the broader use of commercial CBD products for children is an area of ongoing scientific investigation and debate. Understanding what the current research says is crucial for anyone seeking to learn about this topic. The scientific community, including organizations like the World Health Organization (WHO), has reviewed CBD, noting it is generally well-tolerated but also emphasizing that much is still unknown, especially regarding long-term effects in children.
The Science and Mechanism of Cannabidiol
To understand how CBD works, it is essential to look at the body's endocannabinoid system (ECS). Discovered in the early 1990s, the ECS is a complex cell-signaling system that helps regulate a wide range of functions, such as sleep, mood, appetite, memory, and immune response. It consists of endocannabinoids (cannabinoids made by the body), receptors they bind to (CB1 and CB2), and enzymes that break them down. CB1 receptors are abundant in the central nervous system, while CB2 receptors are found mostly in the peripheral nervous system and immune cells.
Unlike THC, the psychoactive compound in cannabis, CBD does not produce a "high." It has a low affinity for CB1 and CB2 receptors. Instead, its mechanism of action is multifaceted. One primary way CBD exerts its effects is by inhibiting the FAAH enzyme, which is responsible for breaking down anandamide, an endocannabinoid often called the "bliss molecule." By increasing anandamide levels, CBD indirectly supports the ECS.
Beyond the ECS, CBD interacts with several other receptor systems. It can influence serotonin receptors (specifically 5-HT1A), which may contribute to its potential effects on anxiety and mood. It also interacts with TRPV1 vanilloid receptors, which are involved in pain and inflammation perception. Furthermore, CBD has been shown to modulate GABA receptors, the primary inhibitory neurotransmitter in the brain, potentially contributing to a calming effect. The metabolism of CBD primarily occurs in the liver and intestines through cytochrome P450 enzymes. This is why CBD can interact with other medications, a significant safety consideration. Oral bioavailability-the amount that enters circulation to have an effect-is relatively low and can be influenced by factors like whether it is taken with food.
Background on CBD Classification
Cannabidiol (CBD) is one of over 100 phytocannabinoids found in the Cannabis sativa plant. It is non-intoxicating, meaning it does not cause the euphoric high associated with tetrahydrocannabinol (THC). Legally, the distinction often depends on the source plant. Hemp is legally defined in the U.S. as cannabis containing no more than 0.3% THC by dry weight. CBD derived from hemp is federally legal, though state laws vary. Conversely, CBD derived from marijuana (cannabis with more than 0.3% THC) remains a federally controlled substance.
The FDA has approved a prescription drug, Epidiolex, which is a purified CBD oral solution, for the treatment of seizures associated with specific severe epilepsy syndromes in children aged one and older. However, the FDA has not approved other CBD products for any therapeutic use and has expressed concerns about the proliferation of unapproved products making unsubstantiated health claims. The World Health Organization (WHO) conducted a critical review and concluded that pure CBD does not appear to have abuse potential or cause serious harm, though it noted the potential for drug interactions.
Safety and Regulatory Considerations
The safety of over-the-counter (OTC) CBD products for children is a primary concern for regulatory bodies and health professionals. Since these products are not regulated by the FDA, there are significant inconsistencies in product quality, purity, and CBD concentration. Studies have found that some products contain less or more CBD than advertised, and some contain undisclosed THC or contaminants like pesticides and heavy metals.
Reported side effects in clinical studies of CBD include tiredness, diarrhea, changes in appetite or weight, and irritability. A significant concern is the potential for liver injury, which has been observed in studies, and the risk of interactions with other medications. Because CBD is metabolized by cytochrome P450 enzymes, it can interfere with the processing of many common drugs, similar to the warning found on grapefruit juice. For pediatric populations, the long-term effects of CBD on a developing brain and body are still largely unknown. Due to these uncertainties, experts generally advise against giving CBD to children unless under the guidance of a healthcare professional.
Comparative Context of CBD Forms
CBD is available in various forms, each with different characteristics affecting how the body absorbs and uses it. The choice of form can impact onset speed, duration of effects, and bioavailability.
| Attribute | CBD Gummies | CBD Capsules | CBD Oil (Sublingual) |
|---|---|---|---|
| Source/Form | CBD extract infused into a chewable gummy. | CBD oil enclosed in a softgel or hard-shell capsule. | CBD extract mixed with a carrier oil, taken under the tongue. |
| Absorption/Metabolic Impact | Slowest onset; must pass through the digestive system and liver (first-pass metabolism), which reduces bioavailability (estimated 13-19%). | Slow onset, similar to gummies. Relies on digestion, but some oil may be absorbed by the stomach lining. | Faster onset; absorbed directly into the bloodstream through mucous membranes under the tongue, bypassing first-pass metabolism for higher bioavailability (estimated 12-35%). |
| Intake Ranges Studied | Doses vary widely by product, typically 5-30 mg per gummy. | Doses are pre-measured, typically 10-50 mg per capsule. | Dosing is flexible and measured with a dropper. Clinical studies have used a wide range, from 25 mg to over 1500 mg daily. |
| Limitations | Lower bioavailability and slower effect. May contain added sugars and artificial ingredients. Inconsistent dosing between brands is a concern. | Slower effect due to digestion. Bioavailability is lower than sublingual oil. | The natural, earthy taste can be unpleasant for some. Less convenient for on-the-go use compared to gummies or capsules. |
| Populations Studied | General adult consumer use. Very limited research in pediatric populations outside of anecdotal reports. | General adult consumer use; some clinical trials use capsules for consistent dosing. | Used across a wide range of clinical trials in both adults and children, including for epilepsy, anxiety, and autism spectrum disorder. |
H3: Population Trade-Offs
For adults, the choice between gummies, capsules, and oil often comes down to convenience, taste, and desired speed of effect. Gummies offer a simple and tasty option, while capsules provide flavorless, pre-measured doses. Oils offer the most control over dosing and faster effects. For pediatric populations, these trade-offs are secondary to safety and precision. The only FDA-approved form for children is a prescription oral solution (similar to an oil), which ensures precise dosing and purity. OTC products, especially gummies, introduce variability and potential contaminants, which pose a greater risk to children.
FAQ: Common Questions About Children's CBD Gummies
1. Is it legal to give CBD gummies to children?
The legality is complex. Hemp-derived CBD (with less than 0.3% THC) is federally legal, but some states have restrictions. Giving a child a product that might contain traces of THC, which is common in the unregulated market, falls into a legal gray area. Only the FDA-approved drug Epidiolex is clearly legal for pediatric use as prescribed.
2. What does research say about CBD for anxiety in children?
Some preliminary evidence, including a case study of a 10-year-old girl with PTSD and a small study on adolescents with social anxiety, suggests CBD may reduce anxiety symptoms. However, these studies are small, and researchers emphasize that more rigorous, large-scale clinical trials are needed to confirm safety and effectiveness for pediatric anxiety.
3. Can CBD gummies help with sleep problems in children?
A case report indicated that CBD oil helped improve sleep in a child with PTSD. However, another study noted that while anxiety scores improved with CBD, sleep scores did not show sustained improvement. Some experts worry that children may develop a tolerance or experience worsening sleep if CBD is stopped.
4. What are the main risks of using non-prescription CBD products for kids?
The primary risks stem from a lack of regulation. Products may have inconsistent CBD and THC levels, or contain harmful contaminants. Known side effects include drowsiness and digestive issues, with more serious concerns being potential liver injury and interactions with other medications. The long-term effects on child development are unknown.
5. Has the World Health Organization (WHO) approved CBD for children?
The WHO has not recommended CBD for general medical use in children but has conducted a pre-review report on pure CBD. The report found that CBD is generally well-tolerated, has a good safety profile, and does not seem to have abuse potential. However, it also highlights that evidence for most conditions is still preliminary and warns of potential drug-drug interactions.
This content is for informational purposes only. Always consult a healthcare professional before starting any supplement.